Myval transcatheter heart valve system in the treatment of severe symptomatic aortic stenosis

Samin K. Sharma, Ravinder S. Rao, Manik Chopra, Anmol Sonawane, John Jose, Gunasekaran Sengottuvelu

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


The transcatheter aortic valve replacement (TAVR) is an established treatment for patients with severe symptomatic aortic stenosis (AS) at prohibitive risk for surgery. It is an alternative treatment to surgical aortic valve replacement in patients with AS at intermediate- and high-surgical risk. Although regulatory authorities extend the indications of TAVR to treat patients at low-surgical risk, the limitations of earlier-generation transcatheter heart valve (THV) systems accelerate the development of improved newer generation of THV systems. Myval™ THV (Meril Life Sciences Pvt. Ltd., Vapi, Gujarat, India) is a newer-generation, balloon-expandable TAVR system with features that facilitate accurate positioning of the bioprosthetic valve and favorable procedural and clinical outcomes. This review summarizes existing preclinical and clinical data on Myval THV for the intervention of symptomatic native AS and lays out the plan for future research program.

Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalFuture Cardiology
Issue number1
StatePublished - Jan 2021
Externally publishedYes


  • balloon-expandable THV
  • severe symptomatic native aortic stenosis
  • surgical risk
  • transcatheter aortic valve replacement
  • transcatheter heart valve systems


Dive into the research topics of 'Myval transcatheter heart valve system in the treatment of severe symptomatic aortic stenosis'. Together they form a unique fingerprint.

Cite this